Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Global Post-Market Clinical Follow-up of the Treovance Stent-Graft for Endovascular Aneurysm Repair: One-Year Results From the RATIONALE Registry

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Commentary: Emergent TAVR During TEVAR

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Pressure Difference Estimation in Carotid Bulbs using Vector Flow Imaging - A Phantom Study

    Research output: Contribution to journalConference articleResearchpeer-review

  2. Commentary on Drug-Eluting Technologies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cutdown Technique is Superior to Fascial Closure for Femoral Artery Access after Elective Endovascular Aortic Repair

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Endovascular aortic repair reduces gluteal oxygenation

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lars Lönn (Member of study group)
  • RATIONALE Investigators (Lars Lönn, members)
View graph of relations

PURPOSE:: To evaluate the safety and performance of the Treovance stent-graft.

METHODS:: The global, multicenter RATIONALE registry (; identifier NCT03449875) prospectively enrolled 202 patients (mean age 73.0±7.8 years; 187 men) with abdominal aortic aneurysms (AAA) suitable for endovascular aneurysm repair (EVAR) using the Treovance. The composite primary safety endpoint was site-reported all-cause mortality and major morbidity. The primary efficacy outcome was clinical success. Further outcomes evaluated included technical success; stent-graft migration, patency, and integrity; endoleak; and aneurysm size changes.

RESULTS:: Technical success was 96% (194/202); 8 patients had unresolved type I endoleaks at the end of the procedure. There was no 30-day mortality and 1% major morbidity (1 myocardial infarction and 1 bowel ischemia). Clinical success at 1 year was confirmed in 194 (96%) patients; 6 of 8 patients had new/persistent endoleaks and 2 had aneurysm expansion without identified endoleak. A total of 8 (4%) reinterventions were required during the mean 13.7±3.1 months of follow-up (median 12.8). At 1 year, the Kaplan-Meier estimate for freedom from reintervention was 95.6% (95% CI 91.4% to 97.8%). Other estimates were 95.5% (95% CI 91.7% to 97.6%) for freedom from endoleak type I/III and 97.4% (95% CI 94.2% to 98.9%) for freedom from aneurysm expansion. Thirteen (6.4%) patients died; no death was aneurysm related.

CONCLUSION:: The RATIONALE registry showed favorable safety and clinical performance of the Treovance stent-graft for the treatment of infrarenal AAAs in a real-world setting.

Original languageEnglish
JournalJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
Issue number6
Pages (from-to)726-734
Number of pages9
Publication statusPublished - Dec 2018

ID: 55695420